Twelve Points Wealth Management LLC Has $4.14 Million Holdings in VanEck Pharmaceutical ETF (NASDAQ:PPH)

Twelve Points Wealth Management LLC decreased its holdings in VanEck Pharmaceutical ETF (NASDAQ:PPH) by 2.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 43,576 shares of the company’s stock after selling 885 shares during the quarter. VanEck Pharmaceutical ETF accounts for approximately 1.3% of Twelve Points Wealth Management LLC’s investment portfolio, making the stock its 14th biggest holding. Twelve Points Wealth Management LLC owned 0.57% of VanEck Pharmaceutical ETF worth $4,141,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Optimum Investment Advisors purchased a new stake in shares of VanEck Pharmaceutical ETF in the second quarter valued at about $27,000. GPS Wealth Strategies Group LLC bought a new stake in VanEck Pharmaceutical ETF in the 2nd quarter worth about $42,000. CWM LLC purchased a new stake in VanEck Pharmaceutical ETF in the 2nd quarter valued at about $55,000. International Assets Investment Management LLC bought a new position in shares of VanEck Pharmaceutical ETF during the 2nd quarter worth approximately $86,000. Finally, Comerica Bank boosted its stake in shares of VanEck Pharmaceutical ETF by 39.4% in the 1st quarter. Comerica Bank now owns 1,337 shares of the company’s stock worth $121,000 after buying an additional 378 shares during the last quarter.

VanEck Pharmaceutical ETF Stock Up 0.2 %

PPH stock opened at $94.80 on Thursday. The business has a 50 day moving average of $96.20 and a 200-day moving average of $92.32. The firm has a market cap of $724.27 million, a PE ratio of 21.04 and a beta of 0.72. VanEck Pharmaceutical ETF has a 12-month low of $74.05 and a 12-month high of $99.51.

VanEck Pharmaceutical ETF Company Profile

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.